Biomarin Pharmaceutical Inc (BMRN)
Working capital turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 2,845,320 | 2,374,190 | 2,068,670 | 1,832,750 | 1,823,140 |
| Total current assets | US$ in thousands | 3,232,430 | 2,956,090 | 2,751,460 | 2,274,380 | 2,342,220 |
| Total current liabilities | US$ in thousands | 606,988 | 1,177,020 | 588,884 | 546,497 | 492,548 |
| Working capital turnover | 1.08 | 1.33 | 0.96 | 1.06 | 0.99 |
December 31, 2024 calculation
Working capital turnover = Revenue ÷ (Total current assets – Total current liabilities)
= $2,845,320K ÷ ($3,232,430K – $606,988K)
= 1.08
The working capital turnover ratio for Biomarin Pharmaceutical Inc has shown some fluctuations over the years. In 2020, the ratio was 0.99, indicating that the company turned over its working capital almost once during that year.
In 2021, the ratio increased to 1.06, suggesting a slight improvement in the efficiency of utilizing working capital to generate revenue. However, in 2022, the ratio decreased to 0.96, indicating a decline in the rate of working capital turnover.
The year 2023 saw a significant improvement in the working capital turnover ratio, reaching 1.33, which suggests that Biomarin Pharmaceutical Inc efficiently utilized its working capital to generate sales during that period.
In 2024, the ratio decreased slightly to 1.08, still showing a relatively healthy turnover of working capital. Overall, the variations in the working capital turnover ratio over the years indicate fluctuations in the company's efficiency in managing its working capital to drive revenue generation.
Peer comparison
Dec 31, 2024